UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000008652 |
|---|---|
| Receipt number | R000010168 |
| Scientific Title | Study to identify the new molecules for liver carcinogenesis from chronic liver deseases and for cancer progeresssion. |
| Date of disclosure of the study information | 2012/08/08 |
| Last modified on | 2020/08/14 20:36:53 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Study to identify the new molecules for liver carcinogenesis from chronic liver deseases and for cancer progeresssion.
Acronym
Study for liver carcinogenesis.
Scientific Title
Study to identify the new molecules for liver carcinogenesis from chronic liver deseases and for cancer progeresssion.
Scientific Title:Acronym
Study for liver carcinogenesis.
Region
| Japan |
Condition
Condition
Chronic liver diseases and hepatocellular carcinoma
Classification by specialty
| Medicine in general | Hepato-biliary-pancreatic medicine |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
The aim of this study is to find the molecules related with liver carcinogenesis from chronic liver deseases, cancer progression and treatment effect. Moreover, we try to establish new treatment using new molecules we find.
Basic objectives2
Bio-availability
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Detection of new molecules, which overexpressed in hepatocellular carcinoma compared to non-tumor tissue.
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients of hepatocellular carcinoma we can take informed concent to use the liver specimens obtained in surgical treatment or tumor biopsy for diagnosis, regardless of sex or age.
Key exclusion criteria
1. The patients who have poorly controlled cardiovascular, hematologic or pulmonary disease
2. The patients with pregnancy
3. The patients with severe depression or other psychiatric disorders
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | Yoichi |
| Middle name | |
| Last name | Hiasa |
Organization
Ehime University Graduate School of Medicine
Division name
Department of Gastroenterology and Metabology
Zip code
791-0295
Address
Shitsukawa, Toon, Ehime 791-0295, Japan
TEL
+81-89-960-5308
hiasa@m.ehime-u.ac.jp
Public contact
Name of contact person
| 1st name | Yoichi |
| Middle name | |
| Last name | Hiasa |
Organization
Ehime University Graduate School of Medicine
Division name
Department of Gastroenterology and Metabology
Zip code
791-0295
Address
Shitsukawa, Toon, Ehime 791-0295, Japan
TEL
+81-89-960-5308
Homepage URL
hiasa@m.ehime-u.ac.jp
Sponsor or person
Institute
Ehime University Graduate School of Medicine
Institute
Department
Personal name
Funding Source
Organization
a Grant-in-Aid for Scientific Research, Japan Society for the Promotion of Science, from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Institutional Review Board, Ehime University Hospital
Address
Shitsukawa, Toon, Ehime
Tel
089-960-5172
rinri@m.ehime-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 08 | Month | 08 | Day |
Related information
URL releasing protocol
Publication of results
Partially published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2007 | Year | 11 | Month | 01 | Day |
Date of IRB
| 2007 | Year | 11 | Month | 01 | Day |
Anticipated trial start date
| 2007 | Year | 11 | Month | 01 | Day |
Last follow-up date
| 2024 | Year | 11 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
We have identified some molecules, which over expressed in hepatocellular carcinoma. We are now analyzing their role for clinical importances.
Management information
Registered date
| 2012 | Year | 08 | Month | 08 | Day |
Last modified on
| 2020 | Year | 08 | Month | 14 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010168
